Brief: Gilead And Carna Biosciences Announce Research And Development Collaboration
25/06/2019 02:32
June 24 (Reuters) - Gilead Sciences Inc GILD.O :
* GILEAD AND CARNA BIOSCIENCES ANNOUNCE RESEARCH AND
DEVELOPMENT
COLLABORATION TO DEVELOP NOVEL IMMUNO-ONCOLOGY THERAPIES
* GILEAD SCIENCES- CARNA WILL RECEIVE AN UPFRONT PAYMENT OF
$20
MILLION & IS ELIGIBLE TO RECEIVE UP TO ADDITIONAL $450 MILLION
IN POTENTIAL MILESTONE PAYMENTS
* CARNA WILL ALSO RECEIVE ROYALTIES ON FUTURE NET SALES
* CARNA WILL ALSO RECEIVE ROYALTIES ON FUTURE NET SALES
* GILEAD WILL ALSO HAVE EXCLUSIVE ACCESS TO CARNA'S
PROPRIETARY
LIPID KINASE DRUG DISCOVERY PLATFORM
* GILEAD- UNDER TERMS, CO WILL LICENSE FROM CARNA WORLDWIDE
RIGHTS
TO DEVELOP & COMMERCIALIZE INHIBITORS AGAINST AN UNDISCLOSED
IMMUNO-ONCOLOGY TARGET
Source text for Eikon: ID:nBw1QbSDQa
Further company coverage: GILD.O
((Reuters.Briefs@thomsonreuters.com;))